HELSINKI, Aug. 28, 2020 /PRNewswire/ -- Nanoform's half year financial report January-June 2020: Positive momentum continues to build after successful IPO, near-term business target: "to acquire more new customers in 2020 than in 2019" achieved in July.
April-June 2020 in brief:
January-June 2020 in brief:
Significant event during H1/2020:
Significant events after H1/2020:
Nanoform's CEO Prof. Edward Hćggström:
The first half of 2020 goes to the history books. The COVID-19 global outbreak that started in China in December 2019, hit Europe and the US hard during March 2020. More or less all global travel between countries was banned and all work that could be done remotely was done from home. Fortunately, our commercial team travelled extensively during 2019 and the beginning of 2020 and introduced our technology to many prospective customers, which made follow-up discussions, negotiations and even signing contracts possible virtually. I'm also pleased that we've been able to initiate discussions with entirely new leads during Q2/2020.
I'm very proud that during the first seven months of 2020 we have won more new customers than we did during the entire 2019. I'm confident that the strong commercial momentum will continue, as starting from September 1, we will have doubled the size of our global commercial team after hiring two experienced US-based business development professionals.
Having met our second short-term business target (the first one we met in April, when the Finnish Medicines Agency gave us GMP status) and having successfully listed Nanoform - here I want to take the opportunity to explicitly thank all investors for the faith you have placed in the Nanoform team, the response we got from you during our roadshow was remarkable and energizing - my focus is now on ensuring that Nanoform enters the next stage on its growth trajectory. By that I mean the world of GMP projects supplying material to clinical trials with the long-term vision to help a billion patients. Based on the work done so far I'm confident that we are on track towards achieving our third and fourth short-term business targets, namely starting our first GMP project before year end 2020 and first dosing of nanoformed Active Pharmaceutical Ingredients (API) in humans in 2021.
None of this can be done without our amazing employees and great partners! My sincere THANK YOU to you all for your continued dedication to Nanoform and for the inspiring and innovative work for which we are known. Our journey has only begun, let's make the coming five years as exciting as the first five have been!
Company near-term business targets for 2020 and 2021 (unchanged):
Company mid-term business targets 2025 (unchanged):
Change in equity and outstanding shares during the reported period:
On June 30, 2020 Nanoform had 66,583,772 (37,006,319) shares. Each share entitles to one vote at the General Meeting of Shareholders. On June 30, 2020, the Group's share capital was EUR 80,000 (EUR 2,500). On June 3, 2020, the Company has issued 20,289,856 and 2,898,551 new shares with directed share issues in connection with the listing. The holders of stock options program 1/2016 exercised their options to subscribe for 1,300,000 shares on April 22, 2020. On June 30, 2020 the Company's total equity was EUR 69.47 million (EUR 12.18 million).
Nanoform Group's key figures, Financial KPI's:
EUR thousand | 4-6/2020 | 4-6/2019 | 1-6/2020 | 1-6/2019 | 1-12/2019 |
Revenue |
191 |
342 |
49 | ||
Gross profit |
159 |
-90 |
262 |
-145 |
-323 |
EBITDA |
-6,348 |
-1,488 |
-10,485 |
-2,488 |
-6,900 |
Operating loss |
-6,622 |
-1,579 |
-10,987 |
-2,663 |
-7,344 |
Loss for the period |
-6,758 |
-1,647 |
-11,345 |
-2,791 |
-7,554 |
Basic EPS (EUR) |
-0.14 |
-0.04 |
-0.23 |
-0.08 |
-0.19 |
Net debt |
-69,751 |
-7,958 |
-69,751 |
-7,958 |
-3,640 |
Net debt excluding lease liabilities |
-74,101 |
-9,748 |
-74,101 |
-9,748 |
-6,626 |
Investments in property, plant and equipment |
-514 |
-360 |
-838 |
-467 |
-1,804 |
Operative free cash flow |
-6,863 |
-1,848 |
-11,322 |
-2,955 |
-8,704 |
Cash and cash equivalents (end of period) |
75,155 |
10,394 |
75,155 |
10,394 |
7,303 |
Nanoform Group's key figures, Operational KPI's:
EUR thousand | 4-6/2020 | 4-6/2019 | 1-6/2020 | 1-6/2019 | 1-12/2019 | |
Number of new projects started during the period | ||||||
Non-GMP |
1 |
0 |
5 |
0 |
2 | |
GMP |
0 |
0 |
0 |
0 |
0 | |
Number of lines (end of the period) | ||||||
Non-GMP |
7 |
4 |
7 |
0 |
4 | |
GMP |
1 |
0 |
1 |
0 |
0 | |
Number of employees (end of the period) |
55 |
33 |
55 |
33 |
43 |
Nanoform's complete half year financial report January-June 2020 can also be found at: https://nanoform.com/en/financial-reports-and-presentations/
Telephone conference for analysts, investors and media:
Nanoform H1/2020 Conference Call Friday August 28th 09:00 EEST (08:00 CEST)
Nanoform will hold a conference call in connection with the Q2/2020 report. Nanoform is represented by CEO Edward Hćggström, CFO Albert Hćggström, CCO Christian Jones, CBO Gonçalo Andrade and Director of Investor Relations Henri von Haartman.
Please call 5-10 minutes prior to the event for a prompt start. Participants Dial in (Access Code: 793554):
Finland (Local) 075 3252542
Denmark (Local) 89 87 50 45
Sweden 0200 123 717
Sweden (Local) 010 884 80 16
Denmark 80 82 00 35
Norway (Local) 815 03 308
United Kingdom 0800 640 6441
United Kingdom (Local) 020 3936 2999
Switzerland (Local) 022 518 90 26
US and all other locations +44 20 3936 2999
Viewing the presentation: www.incommuk.com/ customers/nanoformcall (Access Code: 793554)
For further information, please contact:
Albert Hćggström, CFO
[email protected] / +358 29 370 0150
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
[email protected] / +46 7686 650 11
Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nanoforming services. The Company's patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform's unique technology provides novel opportunities in many value-enhancing drug delivery applications.For more information please visit http://www.nanoform.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Nanoform
These press releases may also interest you
|